Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Sanofi (SNY) wins a pivotal Tzield label expansion into recently diagnosed stage 3 type 1 diabetes
Sanofi (SNY) wins FDA accelerated approval for Tzield in recently diagnosed stage 3 type 1 diabetes, expanding its market beyond screening. Full analysis here.
Is Atara Biotherapeutics quietly preparing for tougher capital allocation choices?
Find out why Atara Biotherapeutics’ board refresh could reshape capital allocation, regulatory strategy and ATRA stock sentiment as investors watch the FDA.
Otsuka Holdings expands neuropsychiatry strategy with $1.23bn Transcend deal structure
Find out how Otsuka’s Transcend Therapeutics acquisition could reshape PTSD drug development and investor sentiment around TSE: 4578.
Why multiple system atrophy could become the biggest test of Alterity Therapeutics’ ATH434 strategy
Find out how FDA alignment on ATH434 could reshape Alterity Therapeutics’ Phase 3 strategy and rare neurology investor outlook.
Why myasthenia gravis could become the next major test for TG Therapeutics’ BRIUMVI franchise
Find out how TG Therapeutics’ BRIUMVI myasthenia gravis data could expand its autoimmune growth story beyond multiple sclerosis.
Why Novartis’ $12bn Avidity bet suddenly looks more interesting after new del-brax data
Find out how Novartis AG’s del-brax data could strengthen its $12bn Avidity Biosciences bet and rare muscle disease strategy.
Alterity Therapeutics (ASX:ATH) has FDA clarity, but Phase 3 funding now tests the rally
Alterity has FDA clarity for ATH434. The bigger question is whether ASX:ATH can fund and execute Phase 3 without losing momentum.
Could Ebglyss’ longer dosing window strengthen Eli Lilly and Company’s dermatology growth strategy?
Find out how Ebglyss’ every-eight-week FDA approval could strengthen Eli Lilly’s dermatology strategy and investor sentiment.
Why Amgen’s Tavneos trouble may be more than just another FDA safety review
Find out why Amgen’s Tavneos review could reshape rare disease drug regulation, investor sentiment, and biotech M&A risk.
Akeso gumokimab approval strengthens China biologics push as psoriasis market heats up
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and boost its autoimmune drug strategy.